Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intralipid + dextrose is a combination used in parenteral nutrition, typically as part of a total parenteral nutrition (TPN) regimen. Intralipid is an intravenous fat emulsion composed primarily of soybean oil, egg phospholipids, and glycerin, providing essential fatty acids and calories. Dextrose is a form of glucose that serves as a carbohydrate energy source. When combined, these components supply both lipids and carbohydrates intravenously to patients who cannot receive adequate nutrition orally or enterally. This combination supports caloric intake, prevents essential fatty acid deficiency (EFAD), and maintains metabolic needs during periods when oral or enteral feeding is not possible or sufficient[1][2][3][5]. The mechanism involves direct provision of macronutrients for cellular metabolism: Intralipid supplies triglycerides metabolized for energy and structural needs; dextrose provides immediate glucose for cellular respiration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on intralipid + dextrose.